Lilly's Zepbound-Containing Regimen Succeeds in Psoriasis Trial

Lilly announced that a regimen including its drug Zepbound demonstrated success in a clinical trial for treating psoriasis.

18 Feb, 12:26 — 18 Feb, 12:28

Post Share

Why this matters

This story is significant because Zepbound, primarily known as a weight-loss drug, has shown success in treating psoriasis, suggesting a potential expansion of its therapeutic applications. This could offer new treatment avenues for psoriasis patients and enhance market opportunities for Eli Lilly beyond its current indications.

Key entitiesEli Lilly Zepbound Taltz

The Story

What 2 sources agree on, dispute, and miss

What sources agree on

Eli Lilly announced the success of a trial for psoriasis.
The successful trial involved a regimen containing the drug Zepbound.

Key claims1 agreed · 4 unverified

✓

Eli Lilly announced the success of a Zepbound-containing regimen in a trial for psoriasis.

agreed·cnbcseeking-alpha

The Zepbound-containing regimen involved the combined use of Zepbound with psoriasis treatment Taltz.

unverified·cnbc

The combined use of Zepbound and Taltz showed better results in a late-stage study.

unverified·cnbc

The regimen improved psoriasis symptoms.

unverified·cnbc

The regimen drove weight loss.

unverified·cnbc

Where they diverge

Specific components of the Zepbound-containing regimen and its additional benefits.

cnbc

This outlet specifies the regimen combined Zepbound with Taltz and resulted in improved psoriasis symptoms and weight loss.

seeking-alpha

This outlet refers generally to a 'Zepbound-containing regimen' without detailing its components or additional benefits.

Coverage gaps

The specific combination of Zepbound with Taltz and the additional benefits of improving psoriasis symptoms and driving weight loss.

Reportedcnbc

Missingseeking-alpha

The Story

Analyzing sources…

Source Diversity

Moderate (27/100)

2 sources— more sources would strengthen this score15/33

Spectrum spread— 2/5 buckets covered8/33

Far L

Left1

Left (1)

cnbc

Center

Right1

Right (1)

seeking-alpha

Far R

Geographic diversity— 1 region4/34

US2

ℹAll sources from US region

ℹOnly 2 sources cover this story

Sources

Showing 2 of 2 sources

cnbcMostly Factual53d ago

Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study

Eli Lilly said on Wednesday the combined use of its weight-loss drug Zepbound with psoriasis treatment Taltz showed better results in a late-stage study.

Read full article →

seeking-alphaMixed53d ago

Lilly says Zepbound-containing regimen succeeded in a trial for psoriasis

Read full article →

Coverage Timeline

First report: seeking-alpha · 18 Feb, 12:26|Full coverage: 2 · 2m|Window: 2m

Left-leaningCenterRight-leaning

seeking-alpha18 Feb, 12:26First to report

Lilly says Zepbound-containing regimen succeeded in a trial for psoriasis

cnbc18 Feb, 12:28Latest update

PERSPECTA

PERSPECTA

Lilly's Zepbound-Containing Regimen Succeeds in Psoriasis Trial

Why this matters

The Story

What sources agree on

Key claims1 agreed · 4 unverified

Where they diverge

Coverage gaps

The Story

Source Diversity

Source Diversity

Sources

Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study

Lilly says Zepbound-containing regimen succeeded in a trial for psoriasis

Coverage Timeline

Lilly says Zepbound-containing regimen succeeded in a trial for psoriasis

Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study

Related Stories

Study Suggests Syphilis-Like Disease Spread in Ancient Vietnam, Challenging Columbus Theory

Understanding and Managing Postpartum Sweating

Protecting Dogs from Viper Bites as Warmer Weather Arrives

Protecting Dogs from Viper Bites as Weather Warms

PERSPECTA

Why this matters

The Story

What sources agree on

Key claims1 agreed · 4 unverified

Where they diverge

Coverage gaps

Coverage matrix